Axogen prices $208.7m share offering to fund BioCircuit deal

Axogen is selling 4.91 million shares at $42.50 each, with proceeds earmarked to finance its pending acquisition of BioCircuit Technologies.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A bright conference room features a long, reflective conference table lined with black chairs, a stack of folders in the foreground, and large windows revealing a blurred city skyline.

Axogen has priced an underwritten public offering of 4,910,000 shares of common stock at $42.50 per share, raising gross proceeds of approximately $208.7 million before underwriting fees and commissions. The Florida-based peripheral nerve repair specialist said the offering is expected to close on 11 September 2026, subject to customary conditions.

The company has also granted underwriters a 30-day option to purchase up to an additional 736,500 shares at the same price, which could lift total gross proceeds if exercised in full. BofA Securities, Jefferies and Wells Fargo Securities are acting as lead book-running managers, with Mizuho Securities as an additional bookrunner and Lake Street Capital Markets as co-manager.

Use of proceeds

Axogen stated that substantially all of the net proceeds will be directed toward the cash consideration payable in connection with its previously announced acquisition of BioCircuit Technologies, along with associated fees and expenses. If the BioCircuit deal does not close, the company said it intends to deploy the proceeds for general corporate purposes, including working capital and capital expenditure. The offering itself is not conditioned on the BioCircuit transaction completing.

BioCircuit Technologies is a company focused on peripheral nerve repair, a field that overlaps directly with Axogen's core business. Axogen's existing product portfolio includes its Avance Nerve Graft, Axoguard Nerve Connector and Axoguard Nerve Protector lines, all targeting the repair and regeneration of damaged peripheral nerves. The BioCircuit acquisition, if completed, would represent a meaningful extension of that platform.

Market context

The peripheral nerve repair market is a relatively specialist segment within medical devices, but it has attracted growing attention as surgical techniques improve and the burden of traumatic and iatrogenic nerve injuries becomes better quantified. Axogen positions itself as the only company focused exclusively on peripheral nerve regeneration and repair at commercial scale, though a number of academic spin-outs and smaller device developers are working on competing approaches, including conduit-based and biologic solutions.

Equity offerings of this size in the medical device space are typically scrutinised by investors for dilution risk, particularly when the target acquisition has not yet been publicly valued. Axogen has not disclosed the headline consideration for the BioCircuit deal, which means the market is pricing the strategic rationale without full visibility on deal economics. That uncertainty is reflected in the conventional underwriter overallotment structure, which gives the syndicate flexibility to stabilise the stock in the weeks following the offering. Investors will be watching for further disclosure on BioCircuit's technology, its pipeline stage, and the terms of the acquisition as Axogen moves toward closing.

Sector

Topic

Geography